NCT06577987 - Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

January 14, 2027

Study Completion Date

March 14, 2027

Conditions

Advanced Solid TumorMetastatic Solid TumorRefractory Solid TumorCancerLung CancerTriple Negative Breast CancerBreast NeoplasmsNeuroendocrine TumorsNeuroendocrine CarcinomaRB1 Gene Mutation

Interventions

DRUG

CID-078 Monotherapy

Cyclin A/B-RxL inhibitor, twice-a-day in repeating 21-day treatment cycles until disease progression or discontinuation criteria.

Trial Locations (10)

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

44106

RECRUITING

UH Seidman Cancer Center, Cleveland

49546

RECRUITING

START Midwest, Grand Rapids

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

84119

RECRUITING

START Mountain, West Valley City

89169

RECRUITING

Comprehensive Cancer Centers of Nevada, Las Vegas

97239

RECRUITING

Oregon Health and Science University, Portland

02215

RECRUITING

Dana Farber Cancer Institute, Boston